Enhanced radiosensitization with interferon-α-2b and cisplatin in the treatment of locally advanced cervical carcinoma

Gynecologic Oncology

Volumn 67, Issue 3, 1997, Pages 309-315

  Stock, Richard G ^a   Dottino, Peter ^a   Jennings, T Scott ^a   Terk, Mitchell ^a   DeWyngaert, J Keith ^a   Beddoe, Ann Marie ^a   Cohen, Carmel ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; UTERINE CERVIX CARCINOMA;

EID: 0031466656     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4879     Document Type: Article

References (36)

1. 1. Perez C, Camel H, Kuske R, et al: Radiation therapy alone in the treatment of carcinoma of the uterine cervix: a 20-year experience. Gynecol Oncol 23:127-140, 1986
2. 2. Jampolis S, Andra J, Fletcher G: Analysis of sites and cause of failure of irradiation in an invasive squamous cell carcinoma of the intact uterine cervix. Radiology 115:681-685, 1975
3. 3. Stock RG, Chen ASJ, Karasak C: Natural history and patterns of failure in node positive cervical cancer. Cancer J Sci Am 2:256-262, 1996
4. 4. Carmichael J, Fergusson RJ, Wolf R, et al: Augmentation of cytotoxicity of chemotherapy by human alpha interferons in human non-small cell lung cancer xenografts. Cancer Res 46:4916-4920, 1986
5. 5. Quesade JR, Reuben F, Manning JT, et al: Alpha interferon for induction of remission in hairy cell leukemia. N Eng J Med 310:15-18, 1984
6. 6. Namba M, Yamamoto S, Tanaka H, et al: In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells. Cancer 54:2262-2267, 1984
7. 7. Bowman A, Fergusson R, Allan S, et al: Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study. Ann Oncol 1:351-353, 1990
8. 8. Angioli R, Bernd-Uwe S, Perras J, et al: In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines. Cancer 71:3717-3725, 1993
9. 9. Ortaldo J, McCoy J: Protective effects of interferon in mice previously exposed to lethal irradiation. Radiat Res 81:262-266, 1980
10. 10. Pillai M, Balaram T, Padmanabhan T, et al: Interleukin 2 and alpha interferon induced in vitro modulation of spontaneous cell mediated cytotoxicity in patients with cancer of the uterine cervix undergoing radiotherapy. Acta Oncol 28:39-44, 1989
11. 11. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. 12. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
13. 13. Cox DR, Oakes D: Analysis of Survival Data. London/New York, Chapman and Hall, 1984
14. 14. Winchester DP, Cox JD: Standards for breast conservation treatment. Ca Center J Clin 2:134-162, 1992
15. 15. Lipsztein R, Kredentser D, Dottino P, et al: Combined chemotherapy and radiation therapy for advanced carcinoma of the cervix. Am J Clin Oncol 10:527-530, 1987
16. 16. Hreshchyshyn M, Aron B, Boronow R, et al: Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 5:317-322, 1979
17. 17. Taylor-Papadimitrou J, Balkwill RFS: Implications of new developments in interferon research. Biochem Biophys Acta 695:49-67, 1982
18. 18. Chang A, Keng P: Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle. Cancer Res 47:4338-4341, 1987
19. 19. Dritschilo A, Mossman K, Gray M, et al: Potentiation of radiation injury by interferon. Am J Clin Oncol (CCT) 5:79-82, 1982
20. 20. Kardamakis D, Gillies N, Souhami R, et al: Recombinant human interferon alpha-2b enhances the radiosensitivity of small cell lung cancer in vitro. Anticancer Res 9:1041-1044, 1989
21. 21. Mason KA, Tonfilon PJ: Unexpected radiation protection with 13-cisretinoic acid plus interferon alpha 2a. Cancer Chemother Pharmacol 33:435-437, 1993
22. 22. Mitropoulos D, Dimopolous M, Kiroudi-Vouldgari A, et al: Neoadjuvant cisplatin and interferon alpha2B in the treatment and organ preservation of penile carcinoma. J Urol 152:1124-1126, 1994
23. 23. Kavanagh J, Lippman S, Paredes-Espinoza M, et al: The combination of 13-cis-retinoic acid and interferon alpha 2a with radiation therapy in squamous cell carcinoma of the cervix. Int J Gynecol Cancer 6:439-444, 1996
24. 24. Eifel PJ, Thoms WW, Smith TL, et al: The relationship between brachytherapy dose and outcome in patients with bulky endocervical tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 28:113-118, 1993
25. 25. Perez CA, Breaux S, Madoc-Jones H, et al: Correlation between radiation dose and tumor recurrence and complications in carcinoma of the uterine cervix: stages I and IIa. Int J Radiat Oncol Biol Phys 5:373-382, 1979
26. 26. Torrisi J, Berg C, Harter K, et al: Phase I combined modality clinical trial of alpha-2-interferon and radiotherapy. Int J Radiat Oncol Biol Phys 12:1453-1456, 1986
27. 27. Eifel P, Morris M, Oswald M, et al: Adenocarcinoma of the uterine cervix. Cancer 65:2507-2514, 1990
28. 28. Marcial VA: Carcinoma of the cervix: present status and future. Cancer 39:169-174, 1974
29. 29. Perez CA, Kuske RR, Camel HM, et al: Analysis of pelvic tumor control and impact on survival in carcinoma of the uterine cervix treated with radiation therapy alone. Int J Radiat Oncol Biol Phys 14:613-621, 1988
30. 30. Eifel PJ, Levenback C, Wharton JT, et al: Time course course and incidence of late complications in patients treated with radiation therapy for FIGO stage Ib carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 32:1289-1300, 1995
31. 31. Malfetano J, Keys H, Kredenster D, et al: Weekly cisplatin and radical radiation therapy for advanced, recurrent, and poor prognosis cervical carcinoma. Cancer 71:3703-3706, 1993
32. 32. Park TK, Lee SK, Kim SN, et al: Combined chemotherapy and radiation for bulky stages I-II cervical cancer: comparison of concurrent and sequential regimen. Gynecol Oncol 50:196-201, 1993
33. 33. Pearcey R, Stuart G, MacLean G, et al: Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervix. Gynecol Oncol 58:34-41, 1995
34. 34. Antonadou D, Cardamakis E, Iliopoulos, et al: Comparative study between exclusive irradiation or combined IFN alpha 2a and isotretinoin in stage IIb and III cervical carcinoma. Int J Radiat Oncol Biol Phys 36 (suppl):219, 1996
35. 35. Pouquier H, Dubois JB, Delard R: Cancer of the uterine cervix: dosimetric guidlines for prevention of late rectal and rectosigmoid complications as a result of radiotherapeutic treatment. Int J Radiat Oncol Biol Phys 8:1887-1895, 1982
36. 36. Roeske JC, Mundt A, Halpern H, et al: Risk of late bladder and rectal complications following definitive radiation therapy for carcinoma of the cervix: a dosimetric analysis. Int J Radiat Oncol Biol Phys 32:(supp) 68, 1995